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There is no doubt about the success of precious metals in the clinic, with,,for example, platinum 
conipounds being widely used in the treatment of cancel; silver compounds being useful 
antimicrobial agents and gold compounds used routinely in the treatment of rheumatoid 
arthritis. The medicinal properties of the other platinum group metals are now being recognised 
and of these ci ruthenium anticancer agent has recently entered the clinic, showing promising 
activity on otherwise resistant tumours. Like all nietul drugs, the activity of the ruthenium 
cornpounds depends on both the oxidation state and the ligands. By manipulating these features 
rutheniurn-centred antimalarial, antibiotic and immunosuppressive drugs have been made. 
I n  addition, ruthenium has unique properties which make it particularly useful in drug design. 
In this review we discuss ruthenium from a clinical stunce and outline the medicinal uses qf 
ruthenium- based compounds. 
Precious metals have been used for medicinal 
purposes for at least 3500 years, when records 
show that gold was included in a variety of medi- 
cines in Arabia and China. At that time precious 
metals were believed to benefit health - because of 
their rarity - but research has now linked the med- 
icinal properties of inorganic drugs to specific 
biological properties. The elucidation of a drug 
mechanism is however complex and the exact 
route of activity for many drugs remains unknown. 
The biological targets or mechanism of action of 
many metal drugs are now being resolved step by 
step, and this information is then used to design 
improved drugs with increased potency and 
reduced side effects. 
Metals in the Clinic 
Perhaps the most well known and best studied 
platinum metals drugs are the anticancer com- 
pounds of platinum itself which, after the 
fortuitous discovery of anticancer properties of 
cisplatin in the 1960s, heralded research into other 
platinum compounds and founded a revolution in 
cancer therapy. Today, many platinum drugs are 
used in the clinic and even more are being evaluat- 
ed in clinical mals, not just to treat cancer but to 
fight a range of diseases, including parasitic and 
bacterial infections. Other metals of the platinum 
group and gold and silver have been used in 
medicine and these are listed in the Table. 
Ruthenium Properties Suited to 
Biological Applications 
There are three main properties that make 
ruthenium compounds well suited to medicinal 
application: 
(i) rate of ligand exchange 
(ii) the range of accessible oxidation states and 
(iii) the ability of ruthenium to mimic iron in bind- 
ing to certain biological molecules. These will be 
briefly described in turn. 
(i) Ligand Exchange 
Many ruthenium complexes have been evaluat- 
ed for clinical applications, particularly in the 
treatment of cancer, due in part, to Ru(II) and 
Ru(I1I) complexes having similar ligand exchange 
kinetics to those of PtQl) complexes. L p n d  
exchange is an important determinant of biological 
activity, as very few metal drugs reach the biologi- 
cal target without being modified. Most undergo 
interactions with macromolecules, such as pro- 
teins, or small S-donor compounds and/or water. 
Some interactions are essential for inducing the 
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Fig. I The uxidation state changes 
of ruthenium in cancer and healthy 
cells. The reductive environment of 
cancer cells favours Ru(II). which is 
more biologically active than 
Ru(III). Hence Ru( III) compounds 
are essentially prodrugs that become 
activated by reduction on reaching 
the cancer cell 
activity 
targeted delivery 
R u ( l l l ) d  b Ru(lll) fromdrug 
administration 
Oxidation: molecular oxygen enzymes 
desired therapeutic properties of the complexes. 
As the rate of hgand exchange is dependent on the 
concentration of the exchangmg hgands in the sui-  
rounding solution, diseases that alter these 
concentrations in cells or in the surroundmg tis- 
sues can have an effect on the activity of the drug. 
(ii) Oxidation State 
Ruthenium is unique amongst the platinum 
group in that the oxidation states Ru(Il), Ru(I1I) 
and R u m  are all accessible under physiological 
conditions. In these oxidation states the ruthenium 
centre is predominantly hexacoordinate with essen- 
tially octahedral geometry, and R u g  complexes 
tend to be more biologically inert than related 
R u m  and (IV) complexes. The redox potential of 
a complex can be modified by varying the hgands. 
In biological systems glutathione, ascorbate and 
single electron transfer proteins are able to reduce 
Ru(IIl) and R u m ,  while molecular oxygen and 
cytochrome oxidase readily oxidise R u m .  
The redox potential of ruthenium compounds 
can be exploited to improve the effectiveness of 
drugs in the clinic. For example, the drug can be 
administered as relatively inert Ru(I1I) complexes, 
which are activated by reduction in diseased tis- 
sues. In many cases the altered metabolism 
associated with cancer and microbial infection 
results in a lower oxygen concentration in these 
tissues, compared to healthy ones, and this pro- 
motes a reductive environment. Cancer cells are 
known to have higher levels of glutathione and a 
lower pH than healthy tissues, creating a strongly 
reducing environment. If the active Rug9 com- 
plex leaves the low oxygen environment, it may be 
converted back to Ru(I1I) by a variety of biologi- 
cal oxidants, see Figure 1. 
Proteins that can catalyse the reduction of 
Ru(I1I) to Ru(II) include mitochondrial and 
microsomal single electron transfer proteins. The 
mitochondrial proteins are of particular interest in 
drug design as apoptosis, the desired mechanism 
for cell death, can be initiated in the mitochondria, 
as well as by other pathways, for instance, by the 
Fas/FasL pathway. Transmembrane electron- 
transport systems can also reduce Ru(I1I) 
complexes outside of the cell and this is hghly rel- 
evant to the mechanism of action of a ruthenium- 
based drug in clinical use which has anticancer 
activity independent of cell entry (vide inpa). 
(iii) Iron Mimicking 
The low toxicity of ruthenium drugs is also 
believed to be due to the ability of ruthenium to 
mimic iron in binding to many biomolecules, 
including serum transferrin and albumin. These 
two proteins are used by mammals to solubilise 
and transport iron, thereby reducing its toxicity. 
Since rapidly dividmg cells, for example microbial- 
ly infected cells or cancer cells, have a greater 
requirement for iron, they increase the number of 
transferrin receptors located on their cell surfaces, 
thereby sequestering more of the circulating meta- 
loaded transferrin. In #uo, the exact increase in 
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Fig. 2 Schematic representation of the selective uptake 
of transferrin by cancer cells. Ruthenium can mimic 
iron in binding to transferrin. Metal-loaded rransferrin 
is delivered to cells according to the number of 
transferrin receptors on their surfaces. As most cancer 
cells have a higher number of transferrin receptors (left), 
compared to healthy cells (right), ruthenium is targeted 
to cancer cells 
radio-labelled ruthenium compounds in cancer 
cells, compared to healthy cells, has been shown to 
range from 2-12 fold, depending on the cell type. 
As the drug is targeted to cancer cells, its toxicity is 
reduced because less of it will reach healthy cells, 
see Figure 2. 
Current Uses of Ruthenium-Based 
Drugs 
The array of clinical applications for some plat- 
inum group metals, see the Table, illustrates the 
versatility of metallodrugs in the clinic. The activi- 
ty of each compound is a function of the oxidation 
state of the metal and the nature of the attached 
lgands. These features dictate not only how the 
drug interacts with the disease target but also the 
biological transformations that occur en route. By 
manipulating these features activity can be fme- 
tuned to maximise the potency but minimise the 
general toxicity of the drugs. 
Immunosuppressants 
Immunosuppressants, for example, cyclosporin 
A, are important clinical agents used in the treat- 
ment of a broad range of diseases, including 
aplastic anaemia, severe eczema, glomerulonephr- 
us, psoriasis, systematic sclerosis and psoriatic 
arthritis. Cyclosporin A has a number of side 
effects including renal disease, hypertension and 
nausea, hence there is a continual drive to develop 
a more effective drug. 
RuQII) complexes with N-donor ligands were 
tested as immunosuppressants, with cis- 
~u(NH3),(Im),], Im is imidazole, see Figure 3, 
being particularly effective. These compounds are 
very stable and have been shown to inhibit the 
antigen-independent phase of T-cell proliferation 
at nanomolar concentrations - a marked improve- 
ment on cyclosporin - and hence have much 
potential for clinical development. 
Antimicrobial 
Ruthenium complexes are active against a wide 
range of parasitic diseases including malaria and 
Chagas’ disease. The activity of organic antimicro- 
bial drugs has been enhanced by bin+ the 
organic molecule to a ruthenium centre. The 
enhancement is due, in part, to the ruthenium 
complex overcoming resistance that the parasite 
has developed to the organic compound alone. 
Malaria threatens over 40 per cent of the world’s 
population and the malaria-causing Phmodium par- 
asite is becoming resistant to some of the most 
successful drugs, such as chloroquine. The resis- 
tance mechanism of Phmodium parasites to 
chloroquine involves a reduced rate of uptake of 
the drug. However, it has been found that metal 
complexes of chloroquine partially restore the anti- 
malarial activity. The RuQl)-chloroquine complex, 
~~Cl~(chloroquine)]~, is 2-5 fold more effective 
than chloroquine alone, suggesting that the ruthe- 
nium complex is taken up by a different 
mechanism to the chloroquine. The smcture of 
~uCl,(chloroq~ine)]~, see Figure 3, has not been 
fully established and some uncertainty remains as 
to its precise structure. It is thought that, once in 
the Phmodirrm parasite, the ruthenium complex 
behaves in a similar way to chloroquine, altering 
the pH of the digestive vacuole of the parasite and 
inhibiting the polymerisation of heme (the heme is 
toxic to the parasite which therefore dies). 
The T@anosoma me parasite causes Chagas’ 
disease. Chagas’ disease affects millions of people 
in Latin America and is incurable. The current 
treatment involves noxious organic drugs, the dose 
being limited by the toxicity of the therapy. Once 
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Some Medicinal Properties of the Precious Metals 
(Not all of these compounds have been clinically approved) 
Ru 
Immunosuppressant 
Cancer 
Dental alloys 
Microbial (malaria and 
Chagas’ disease) 
Antibiotic 
Septic shock 
I 
0s 
Dental alloys 
Microbial (Leishmaniasis) 
Rheumatoid arthritis 
Rh 
Cancer 
Radiosensitisers 
Dental alloys 
Microbial (malaria and 
Leischmaniasis) 
Bacterial infections 
Ir 
Radioisotopes in cancer 
again, the effectiveness of these organic drugs 
can be dramatically enhanced by coordination to 
ruthenium centres. 
Antibiotics 
Coordinating ruthenium to organic antibiotic 
compounds often results in %her in vjtm activity. 
A good example is the ruthenium(III) derivative of 
thiosemicarbazone; this exhibits a 70 per cent 
increase in antibiotic activity against the Gram 
negative bacteria Salmonelka @bi and Entembacteria 
fmcaks. It is postulated that the improved activity 
arises from the delocalisation of the positive 
charge between the organic moiety and the metal 
ion, which favours the drug entering the normal 
cellular processes of the bacteria. However, it is 
also possible that the difference in activity stems 
from the ability of R u m  to bind to biological 
molecules, in a similar way as iron. It is believed 
that siderophore compounds are secreted by 
microorganisms to sequester iron from their sur- 
rounding environment. Therefore, if the 
rutheniumo complexes also bind to siderophores 
they wiU be more readily taken up by the cell. 
Nitric Oxide Scavengers 
Nimc oxide (NO) plays a central role in many 
physiological processes indudmg agnalhg, regula- 
tion of cardiovascular function and immunological 
Pd 
Viral (leukaemia and 
HIV) 
Cancer 
Dental alloys 
PI 
Cancer 
Dental alloys 
Microbial 
Anti-HIV 
Ag 
Dental alloys 
Smoking 
Microbial 
Au 
Cancer 
Viral (HIWAIDS) 
Bronchial asthma 
Microbial (malaria) 
Rheumatoid arthritis 
response to microorganisms and tumour cells. 
Consequently, malfunction of NO production 
results in many physiological symptoms. 
Some ruthenium@) polyaminocarboxylates, 
such as -6245 and AMD1226, see Figure 3, 
have been shown to enhance the activity of vaso- 
constrictor drugs and are proposed for the 
treatment of diseases that involve overproduction 
of NO includmg stroke, septic shock, arthritis, 
inflammatory bowel disease, epilepsy and diabetes. 
The edta complexes Kpu(Hedta)OH;] and 
Kpu(Hedta)C1] exist in equilibrium in aqueous 
solution. Both species bind NO rapidly and 
strongly, resulting in the reduction of the Ru(IIl) 
ion to form a linear Rum-NO adduct. 
Anticancer Activity 
Despite the success of platinun-based anti- 
cancer compounds in the dinic, there is still a need 
for new and improved metal-based anticancer 
drugs. The need for new drugs is fuelled by the 
inability of platinum compounds to tackle some 
types of cancer of hlgh social incidence and by the 
associated toxic side effects of the current plat- 
inum compounds in clinical use. 
Platinum anticancer drugs bind DNA, causing 
damage that prevents protein synthesis and repli- 
cation causing cell death. The success of platinum 
anticancer drugs has biased the screening of new 
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Fig. 3 The structures of various medicinal rutheriiuni cornplexes. The structure of the chloroquine complex 
[RuCI2(chloroquine)lz remains uncertciin. NAMI is the Nri' snlt and NAMI-A is the iniidrrzoliian .ctrlt. RAPTA 
compounds, with CSHO, GH.Me, C~H&le'Pr-1.4 and &Wees. htive been ninde 
metal-based anticancer compounds towards look- 
ing for damage caused to DNA. Many Ru(Il), 
Ru(I1I) and R u m  complexes with amine, 
dimethylsulfoxide, imine, polyaminopolycarboxy 
late, and N-heterocyclic ligands have been found 
to bind to DNA, see Figure 3. However, many of 
these compounds are barely soluble in aqueous 
solution, which is necessary to allow efficient 
administration and transport. Solubility has been 
increased by using dialkyl sulfoxide derivatives, 
such as [&uns-RuC~(DMSO)Im] , N M - A ,  
see Figure 3, which is now recognised as the most 
successful ruthenium-based anticancer compound. 
Interestingly, although NAMI-A can bind 
DNA, in vivo DNA damage does not appear to be 
part of its anticancer mechanism. 
In general, anticancer activity hinges on the 
ability of a drug to bring about apoptosis (pro- 
grammed cell death) of the tumour cells. 
Apoptosis is a complicated process by which the 
cell 'commits suicide' in a controlled manner such 
that there is no cell debris or damage done to SUE 
rounding cells. This process is perhaps best 
illustrated on a cellular level using neuroblastoma 
cell lines: growing cells are semi-differentiated, 
forming irregular shapes that can be clearly distin- 
guished from the spherical apoptotic bodies, see 
Figure 4. Alternatively cells can die by a process 
called necrosis, which is less controlled, and caus- 
es inflammation and damage to adjacent cells. 
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There are many mechanisms by which apoptosis 
can be initiated involving interactions of drugs 
with both DNA and proteins. Some ruthenium 
complexes have been shown to damage DNA, 
either directly or indirectly, for example, by posi- 
tioning radiosensitisers close to the DNA. In 
addition to DNA bindug ruthenium compounds 
interact with proteins, and it is likely that both 
activities contribute to the anticancer properties of 
the compounds. 
(a) DNA Damaging Agents 
A number of ruthenium compounds have been 
shown to bind DNA in vjh and there is a direct 
correlation between this activity and the cytotoxi- 
city of Ru(III) am(m)ine complexes in tissue 
culture. The mechanism of DNA bin- has been 
probed and certain ruthenium complexes form 
cross-links between DNA strands - possibly 
favoured due to the steric restrictions imposed by 
the octahedral geometry of the complexes. This 
bin- mechanism differs from the intrastrand 
cross-links favoured by cisplatin, and consequent- 
ly the cancer cell lines that have developed 
resistance to cisplatin by accelerating the rate of 
repair of intrastrand cross-links are st i l l  susceptible 
to ruthenium anticancer drugs. 
Interestingly, it has been demonstrated that 
R u O  complexes are far more reactive towards 
DNA than RuQIIT) AND R u m  and it is therefore 
possible that the anticancer activity of Ru(III) 
involves initial reduction to R u m  at the tumour 
site, promoted by the altered physicochemical 
environment in tumour cells (I& s~pm) .  If this 
hypothesis is correct then R u m  complexes are 
essentially prodrugs. However, there is growing evi- 
dence to show that protein interactions are also 
extremely important in the anticancer activity of 
ruthenium compounds and these interactions could 
occur with the ruthenium in either oxidation state. 
(b) Radiosensitisers 
Radiation therapy is routinely used against 
some types of cancer. This treatment can be 
enhanced by using nitroimidazoles and halogenat- 
ed pyrimidine radiosensitisers (compounds that 
increase the irradiation sensitivity of the target 
cells). As the activity of these compounds depends 
on their proximity to DNA, coordinating 
radiosensitisers to metals that are able to bind to 
DNA, for example platinum and ruthenium, 
enhances the radiosensitising properties. 
The two key features of an effective radiosensi- 
tiset are the ability to bind DNA and the redox 
potential of the bound complex. Strong DNA 
bin- affinity is a feature of many ruthenium 
compounds, although not all have dosemitising 
activity. This activiq depends upon the compound 
having a high reduction potential, which can be 
optimised by the use of appropriate ligands. 
For example, the nitroimidazole complex, 
RuClz(DMSO)z(4-N021m)2, see Figure 3, is one of 
the most effective radiosensitisers having both a 
hgher activity and a lower toxicity than 4-NOz- 
imidazole alone. 
(c) Photodynamic Therapy 
As with radiotherapy, photodynamic therapy 
uses chemicals targeted to diseased cells. The 
chemicals become cytotoxic when exposed to 
electromagnetic radiation. For example, nitrosyl- 
ruthenium@) complexes release NO on 
reduction; the reduction may be triggered using 
photodynamic methods. Until recently, the appli- 
cation of photodynamic therapy was restricted by 
the poor accessibility to cancer cells, but a unique 
approach using ruthenium complexes has been 
developed which overcomes these restrictions. 
This new method of therapy centres on the 
Mossbauer absorption of y-rays by ruthenium; this 
can induce emission of Auger electrons which 
damage the DNA to which the Ru is bound. 
(d) Antimitochondrial 
Apoptosis can be initiated by more than one 
pathway, one being via the mitochondria (the sub- 
cellular compartments associated with energy and 
heat generation). Consequently any compounds 
that target these structures are of great interest as 
anticancer drugs. Ruthenium red, see Figure 3, is 
routinely used by biologists to sta in  mitochondria 
selectively, as it binds to the calcium channels on 
their surfaces and has long been known to inhibit 
tumour cell growth, but its toxicity is too great for 
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Fig. 4 Photographs of human neuroblastoma cells in culture grow to a high density and have an irregular shape (left). 
After incubation with 1.3 pM of the ruthenium drug RAPTA-C there are fewer cells in the culture (right). The smooth, 
more spherical appearance of the remaining cells is characteristic of apoptotic bodies, indicating cell death is 
occurring by apoptosis. Each cell has the average dimensions of 20-40 pm 
use in the clinic. It is possible that the anticancer 
mechanism of some other ruthenium compounds 
may involve mitochondtial interactions. However, 
many ruthenium compounds with putative antitu- 
mour activity are unlikely to act like ruthenium red. 
(e) Antimetastases 
A particularly challenging area of cancer thera- 
py is the treatment of metastases. Metastasis 
occurs at a late stage of the disease and involves 
the escape of cells fiom the primary tumour and 
their reestablishment at distinct secondary loca- 
tions. The metastases are normally dormant and 
are often suppressed by hormones secreted from 
the primary tumour. However, if the primary 
tumour is removed or there are M e r  genetic 
changes in the metastases, growth can begin. 
Tumour growth beyond about 1 mm3 requires a 
blood supply, and the formation of the necessary 
blood vessels is termed angiogenesis. Some 
antimetastases drugs restrict angiogenesis, for 
example angiostatin, throbospondin and badmas- 
tat, but statistics show that once this process has 
occurred the chance of five-year survival drops by 
about 50 per cent, dependmg upon the type of 
cancer. 
The first ruthenium anticancer drug to progress 
through clinical trials, [hzm-RuCL+(DMSO)Im]- 
m, NAMI-A, see Figure 3, is strongly active 
against tumour metastases. NAMI-A appears to 
alter protein expression, either by binding to pro- 
teins or to RNA, causing thickening of the protein 
layer surroundmg turnouts and metastases. As a 
result the tumour becomes isolated, preventing 
escape of metastasing cells and reducing the blood 
flow, which ultimately suffocates it. Only a very 
small portion of the drug reaches the tumour tar- 
get and its activity appears to be independent of its 
concentration in tumour cells. Rather, it appears 
that NAMI-A has an extracellular mode of activity 
centring on interactions with proteins. 
In our own laboratory we have investigated the 
role of the llgands attached to ruthenium in the 
passive diffusion of the drug across cell mem- 
branes, facilitating the movement of the drug into 
and within cells. A series of drugs of formula 
[Ru(arene)Cl~PTA], RAPTA, see Figure 3, have 
been developed that interact with proteins and 
DNA in v j h ,  triggering apoptosis in human cancer 
cell lines. Thepcymene derivative, RAPTA-C, has 
activity against, for example, SK-N-SH neuroblas- 
toma cells, inducing apoptosis in nanomolar 
concentrations, see Figure 4. This cell line was 
derived from the metastases of a human neuro- 
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blastoma that had metastasised to the bone mar- 
row. Figure 4 shows structurally distinct forms. In 
tissue culture, cells grow in the S-form, which is 
partially differentiated and characterised by the 
irregular shapes of the cells. These cells undergo 
two responses to stress: full differentiation or cell 
death. Full differentiation is observed by the more 
‘dendritic’ appearance of the cells, which occurs 
1-3 hours after the stress. Subsequently cells either 
dedifferentiate back to the S phase - if the stress 
can be overcome - or die. 
Concluding Remarks 
Ruthenium drugs are particularly important in 
the clinic due to their low toxicity. This is in part 
due to the ability of ruthenium to mimic the bind- 
ing of iron to biomolecules, exploiting the 
mechanisms that the body has evolved for non- 
toxic transport of iron. In addition, the redox 
potential between the different accessible oxida- 
tion states occupied by ruthenium enables the 
body to catalyse oxidation and reduction reactions, 
depending on the physiological environment. As 
demonstrated for cancer tissues, but also true in 
other diseased states, the biochemical changes that 
accompany disease alter the physiological environ- 
ment, enabling ruthenium compounds to be 
selectively activated in diseased tissues. These two 
features combine to give ruthenium drugs a 
remarkably low toxicity compared to other plat- 
inum group metal compounds and therefore make 
ruthenium compounds promising in the clinic. 
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Thiazepinones Synthesis with Rhodium 
Thiazepinones are pharmaceuticals with poten- 
tial use in the treatment of heart and inflammatory 
diseases. The 7-membered heterocycles have been 
prepared in multistep syntheses in which chirality 
is introduced before or during a transformation. 
Researchers at the University of Ottawa, 
Canada, now report the synthesis of thiazepinones 
using cyclohydrocarbonylative ting expansion of 
acetylenic thiazoles in the presence of CO and Hz, 
via the zwitterionic rhodium complex catalyst (?f- 
C&lJ3Ph&Rh’(l,5-COD) with added triphenyl 
phosphite (B. G. Van den Hoven and H. Alper,]. 
Am. Chsm. SOC., 2001,123, (6), 1017-1022). 
The transformation of the simple and function- 
alised 5-membered acetylenic thiazoles with CO 
and Hz to 7-membered 2-(Z)-6-(@-4H-[1,4]-thi- 
azepin-5-ones occurred in 61 to 90 per cent yields 
with good chemo- and regioselectivities, at 
70-1 10°C, after 18 to 36 hours. A model substrate 
of 2-hex-1-ynylthiazole was used to optimise the 
cyclohydrocarbonylation and ring expansion of 2- 
acetylenic thiazoles. The acetylenic unit can have 
various subsdruents in positions 4 and 5 of the thi- 
azole ring as well as akyl-, ether-, ester-, vinyl-, and 
ary-substituted alkynes at position 2. The process 
is general and may be pharmaceutically interesting. 
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